Cliff Asness's HALO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 968,511 shares of Halozyme Therapeutics, Inc. (HALO) worth $71.03 M, representing 0.05% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 589,711 shares. Largest reduction occurred in Q1 2016, reducing 61,148 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +26,050 | Add 0.00% | 26,049 | $6.72 |
| Q2 2013 | +20,401 | Add 0.00% | 20,400 | $7.94 |
| Q4 2013 | +80,055 | Add 392.43% | 100,455 | $14.99 |
| Q1 2014 | +12,300 | Add 12.24% | 112,755 | $12.70 |
| Q2 2014 | -47,800 | Reduce 42.39% | 64,955 | $9.88 |
| Q3 2014 | -16,400 | Reduce 25.25% | 48,555 | $9.10 |
| Q4 2014 | -28,155 | Reduce 57.99% | 20,400 | $9.66 |
| Q1 2015 | +13,200 | Add 64.71% | 33,600 | $14.26 |
| Q2 2015 | +71,842 | Add 213.82% | 105,442 | $22.58 |
| Q3 2015 | -9,212 | Reduce 8.74% | 96,230 | $13.43 |
| Q4 2015 | -9,171 | Reduce 9.53% | 87,059 | $17.33 |
| Q1 2016 | -61,148 | Reduce 70.24% | 25,911 | $9.46 |
| Q2 2016 | -10,282 | Reduce 39.68% | 15,629 | $8.64 |
| Q4 2016 | -83 | Reduce 0.53% | 15,546 | $9.84 |
| Q2 2017 | +8,202 | Add 52.76% | 23,748 | $12.80 |
| Q3 2017 | +90,500 | Add 381.08% | 114,248 | $17.37 |
| Q4 2017 | +48,577 | Add 42.52% | 162,825 | $20.26 |
| Q1 2018 | +8,948 | Add 5.50% | 171,773 | $19.59 |
| Q4 2018 | -35,388 | Reduce 20.60% | 136,385 | $14.63 |
| Q1 2019 | +958 | Add 0.70% | 137,343 | $16.10 |
| Q2 2019 | -617 | Reduce 0.45% | 136,726 | $17.18 |
| Q3 2019 | -147 | Reduce 0.11% | 136,579 | $15.51 |
| Q4 2019 | -18,409 | Reduce 13.48% | 118,170 | $17.73 |
| Q1 2020 | -33,804 | Reduce 28.61% | 84,366 | $17.99 |
| Q2 2020 | +19,836 | Add 23.51% | 104,202 | $26.81 |
| Q3 2020 | -12,246 | Reduce 11.75% | 91,956 | $26.28 |
| Q4 2020 | -16,542 | Reduce 17.99% | 75,414 | $42.71 |
| Q1 2021 | -1,581 | Reduce 2.10% | 73,833 | $41.69 |
| Q2 2021 | -2,581 | Reduce 3.50% | 71,252 | $45.42 |
| Q3 2021 | -7,404 | Reduce 10.39% | 63,848 | $40.67 |
| Q4 2021 | -4,454 | Reduce 6.98% | 59,394 | $40.21 |
| Q1 2022 | -1,906 | Reduce 3.21% | 57,488 | $39.89 |
| Q2 2022 | -3,288 | Reduce 5.72% | 54,200 | $44.00 |
| Q3 2022 | +4,137 | Add 7.63% | 58,337 | $39.55 |
| Q4 2022 | +5,431 | Add 9.31% | 63,768 | $56.90 |
| Q1 2023 | -1,444 | Reduce 2.26% | 62,324 | $38.19 |
| Q2 2023 | -5,406 | Reduce 8.67% | 56,918 | $36.07 |
| Q3 2023 | -6,655 | Reduce 11.69% | 50,263 | $38.20 |
| Q4 2023 | -5,257 | Reduce 10.46% | 45,006 | $36.96 |
| Q1 2024 | +502 | Add 1.12% | 45,508 | $40.68 |
| Q2 2024 | +2,265 | Add 4.98% | 47,773 | $52.36 |
| Q3 2024 | +4,752 | Add 9.95% | 52,525 | $57.24 |
| Q4 2024 | +432 | Add 0.82% | 52,957 | $47.81 |
| Q1 2025 | -19,819 | Reduce 37.42% | 33,138 | $63.81 |
| Q2 2025 | +345,662 | Add 1043.10% | 378,800 | $52.02 |
| Q3 2025 | +589,711 | Add 155.68% | 968,511 | $73.34 |
Cliff Asness's Halozyme Therapeutics Investment FAQs
Cliff Asness first purchased Halozyme Therapeutics, Inc. (HALO) in Q4 2012, acquiring 26,049 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Halozyme Therapeutics, Inc. (HALO) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2025, adding 968,511 shares worth $71.03 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 968,511 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $71.03 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.05% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Halozyme Therapeutics, Inc. (HALO) was 968,511 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.